Sponsor |  squiffy2 | Jul 16, 4:46am |
Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced today that patients are being enrolled for the BRAVO Phase III pivotal trial. BRAVO is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex® .
The BRAVO trial, which was initiated in April this year, aims to enroll approximately 1,200 patients with relapsing-remitting multiple sclerosis (RRMS). A second global Phase III trial of laquinimod including 1,000 patients, ALLEGRO, is also ongoing and recruiting patients globally. "All currently approved multiple sclerosis (MS) treatments are administered via injection or infusion.
The ability to provide a safe and effective oral treatment option would be a significant advancement for the treatment of MS," said Dr. Timothy Vollmer, Medical Director, Rocky Mountain MS Center, Denver, Colorado, and principal investigator of the BRAVO study. "Additionally, the mode of action for laquinimod is unlike any other MS compound, existing or experimental. We are hopeful that this research will expand our abilities to combat the disease through novel targeting............."
For the full article please go to MSRC: MS Research News : Drugs : Laquinimod - msrc.co.uk/index.cfm [msrc.co.uk/index.cfm] |
|
Multiple Sclerosis → Discussion